JP2017537165A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017537165A5 JP2017537165A5 JP2017548369A JP2017548369A JP2017537165A5 JP 2017537165 A5 JP2017537165 A5 JP 2017537165A5 JP 2017548369 A JP2017548369 A JP 2017548369A JP 2017548369 A JP2017548369 A JP 2017548369A JP 2017537165 A5 JP2017537165 A5 JP 2017537165A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- max
- target
- solabegron
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- LLDXOPKUNJTIRF-QFIPXVFZSA-N solabegron Chemical compound C([C@H](O)C=1C=C(Cl)C=CC=1)NCCNC(C=1)=CC=CC=1C1=CC=CC(C(O)=O)=C1 LLDXOPKUNJTIRF-QFIPXVFZSA-N 0.000 claims description 19
- 229950009659 solabegron Drugs 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 10
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 87
- 238000011282 treatment Methods 0.000 claims 16
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 10
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 5
- 206010019280 Heart failures Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 230000036506 anxiety Effects 0.000 claims 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 5
- 239000002677 5-alpha reductase inhibitor Substances 0.000 claims 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 4
- 108030001720 Bontoxilysin Proteins 0.000 claims 4
- 229930003827 cannabinoid Natural products 0.000 claims 4
- 239000003557 cannabinoid Substances 0.000 claims 4
- 238000012377 drug delivery Methods 0.000 claims 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- 230000007383 nerve stimulation Effects 0.000 claims 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 4
- 150000003180 prostaglandins Chemical class 0.000 claims 4
- 239000012268 protein inhibitor Substances 0.000 claims 4
- 229940121649 protein inhibitor Drugs 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 210000002972 tibial nerve Anatomy 0.000 claims 4
- 230000001052 transient effect Effects 0.000 claims 4
- 206010020853 Hypertonic bladder Diseases 0.000 claims 3
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 3
- 208000005107 Premature Birth Diseases 0.000 claims 3
- 206010036590 Premature baby Diseases 0.000 claims 3
- 229940053031 botulinum toxin Drugs 0.000 claims 3
- 229940065144 cannabinoids Drugs 0.000 claims 3
- 208000020629 overactive bladder Diseases 0.000 claims 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 3
- 108010084938 adenovirus receptor Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000001022 anti-muscarinic effect Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000027939 micturition Effects 0.000 claims 2
- 239000008188 pellet Substances 0.000 claims 2
- 208000017497 prostate disease Diseases 0.000 claims 2
- 239000003422 purinergic receptor affecting agent Substances 0.000 claims 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 206010029446 nocturia Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 2
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462087021P | 2014-12-03 | 2014-12-03 | |
| US62/087,021 | 2014-12-03 | ||
| PCT/US2015/063795 WO2016090168A1 (en) | 2014-12-03 | 2015-12-03 | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017537165A JP2017537165A (ja) | 2017-12-14 |
| JP2017537165A5 true JP2017537165A5 (enExample) | 2019-01-10 |
Family
ID=56092482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548369A Ceased JP2017537165A (ja) | 2014-12-03 | 2015-12-03 | 下部尿路系症状を対象とした徐放性ソラベグロンの組成物及び使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9956194B2 (enExample) |
| EP (1) | EP3226849A4 (enExample) |
| JP (1) | JP2017537165A (enExample) |
| KR (1) | KR20170086659A (enExample) |
| CN (1) | CN107205964A (enExample) |
| AU (1) | AU2015358378A1 (enExample) |
| CA (1) | CA2969405A1 (enExample) |
| EA (1) | EA201791225A1 (enExample) |
| HK (1) | HK1245117A1 (enExample) |
| IL (1) | IL252628A0 (enExample) |
| MX (1) | MX2017007054A (enExample) |
| WO (1) | WO2016090168A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| MX2017007054A (es) | 2014-12-03 | 2018-05-02 | Velicept Therapeutics Inc | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |
| CN108290824B (zh) | 2015-10-23 | 2022-03-11 | B3Ar治疗股份有限公司 | 索拉贝隆两性离子及其应用 |
| WO2017210700A1 (en) * | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| KR20250099259A (ko) | 2017-06-06 | 2025-07-01 | 유로반트 사이언시즈 게엠베하 | 과민성 방광의 치료를 위한 비베그론의 용도 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| TW202038963A (zh) | 2018-12-05 | 2020-11-01 | 瑞士商優洛凡特科學公司 | 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性前列腺增生之男性中膀胱過動症症狀之用途 |
| GB201901186D0 (en) | 2019-01-29 | 2019-03-20 | Univ Of Portsmouth Higher Education Corporation | Method |
| EP4313019A4 (en) * | 2021-03-31 | 2025-02-12 | B3AR Therapeutics, Inc. | Compositions of micronized solabegron and methods of use |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL124473C (enExample) | 1960-07-26 | |||
| DE2965655D1 (en) | 1978-06-28 | 1983-07-21 | Beecham Group Plc | Secondary amines, their preparation, pharmaceutical compositions containing them and their use |
| GB8519154D0 (en) | 1985-07-30 | 1985-09-04 | Ici Plc | Aromatic ethers |
| JPH0236571B2 (ja) * | 1986-04-11 | 1990-08-17 | Otsuka Pharma Co Ltd | Jizokuseiseizai |
| DE3934436A1 (de) | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| US5061727A (en) | 1990-05-04 | 1991-10-29 | American Cyanamid Company | Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles |
| NO179246C (no) | 1991-11-20 | 1996-09-04 | Sankyo Co | Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav |
| WO1995033724A1 (en) | 1994-06-09 | 1995-12-14 | Glaxo Group Limited | Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists |
| US5677346A (en) | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
| CZ126598A3 (cs) | 1995-10-26 | 1998-09-16 | Mitsubishi-Tokyo Pharmaceuticals, Inc. | Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem |
| US6123961A (en) | 1996-09-25 | 2000-09-26 | Bridge Pharma, Inc. | Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin |
| GB9812709D0 (en) | 1998-06-13 | 1998-08-12 | Glaxo Group Ltd | Chemical compounds |
| IL142896A0 (en) * | 1998-11-02 | 2002-04-21 | Elan Corp Plc | Multiparticulate modified release composition |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| GB9929297D0 (en) | 1999-12-11 | 2000-02-02 | Glaxo Group Ltd | Process |
| EP1258253A1 (en) | 2000-01-28 | 2002-11-20 | Asahi Kasei Kabushiki Kaisha | Novel remedies with the use of beta3 agonist |
| US6525202B2 (en) | 2000-07-17 | 2003-02-25 | Wyeth | Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| US6451814B1 (en) | 2000-07-17 | 2002-09-17 | Wyeth | Heterocyclic β-3 adrenergic receptor agonists |
| US6444685B1 (en) | 2000-07-17 | 2002-09-03 | Wyeth | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists |
| US6395762B1 (en) | 2000-07-17 | 2002-05-28 | American Home Products Corporation | Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists |
| GB0102407D0 (en) | 2001-01-31 | 2001-03-14 | Glaxo Group Ltd | Process |
| US7034053B2 (en) | 2001-01-31 | 2006-04-25 | Smithkline Beecham Corporation | Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors |
| US7709677B2 (en) | 2001-01-31 | 2010-05-04 | Glaxosmithkline Llc | Process of preparing arylethanoldiamines |
| KR20040047747A (ko) * | 2001-03-13 | 2004-06-05 | 펜웨스트 파머슈티칼즈 컴파니 | 변시치료 제형 |
| WO2003024483A1 (fr) | 2001-09-11 | 2003-03-27 | Fujisawa Pharmaceutical Co., Ltd. | Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire |
| TW200800953A (en) | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
| EP1424079A1 (en) | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
| WO2005042021A2 (de) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmazeutische zusammensetzung enthaltend einen beta-3-adrenozeptor-agonisten und einen alpha antagonisten und/oder einen 5-alpha reduktase-hemmer |
| DE10352132A1 (de) | 2003-11-04 | 2005-06-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten |
| JP4838724B2 (ja) | 2003-11-27 | 2011-12-14 | デヴェロゲン アクチエンゲゼルシャフト | ニュールツリンを用いる糖尿病の予防と治療方法 |
| ES2390879T3 (es) | 2003-12-31 | 2012-11-19 | Actavis Group Ptc Ehf. | Formulaciones de atomoxetina |
| EP1550447A1 (en) | 2004-01-02 | 2005-07-06 | Schering Aktiengesellschaft | Menstrual cycle control and improvement of conception rates in females |
| WO2005077364A1 (ja) | 2004-02-18 | 2005-08-25 | Yamanouchi Pharmaceutical Co., Ltd. | ソリフェナシンの経皮投与製剤およびその経皮透過改善方法 |
| JP2008516909A (ja) | 2004-10-18 | 2008-05-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 前立腺及び下部泌尿生殖路の病気を治療するためのβ−３アゴニストの使用 |
| KR101356748B1 (ko) | 2005-04-19 | 2014-02-06 | 스미스클라인 비이참 (코르크) 리미티드 | 약제 조성물 |
| CN101242813A (zh) * | 2005-06-20 | 2008-08-13 | 依兰药物国际有限公司 | 包含芳基-杂环化合物的毫微粒和控制释放组合物 |
| EP1769792A1 (de) | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
| ITMI20061581A1 (it) | 2006-08-04 | 2008-02-05 | Univ Bari | Ligandi del recettore beta-3 adrenergico e loro uso in terapia |
| EP1967202A1 (en) | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
| EP2141992A1 (en) | 2007-03-29 | 2010-01-13 | Merck & Co., Inc. | Combination therapy for the treatment-of lower urinary tract symptoms |
| GB0714790D0 (en) | 2007-07-30 | 2007-09-12 | Jagotec Ag | Improvements in or relating to organic compounds |
| SI2216021T1 (sl) | 2007-11-02 | 2013-01-31 | Astellas Pharma Inc. | Farmacevtski sestavek za zdravljenje prekomerno aktivnega sečnega mehurja |
| CA2719907A1 (en) | 2008-04-04 | 2009-10-08 | Merck Sharp & Dohme Corp. | Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists |
| PE20091825A1 (es) | 2008-04-04 | 2009-12-04 | Merck & Co Inc | Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3 |
| EP2181707A1 (en) | 2008-11-04 | 2010-05-05 | Astellas Ireland Co., Ltd. | Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent |
| US8778998B2 (en) | 2009-04-10 | 2014-07-15 | Auspex Pharmaceuticals, Inc. | Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| US8618144B2 (en) | 2009-05-08 | 2013-12-31 | Merck Sharp & Dohme Corp | Pyrrolidine-derived beta 3 adrenergic receptor agonists |
| WO2010147830A2 (en) | 2009-06-15 | 2010-12-23 | Auspex Pharmaceuticals, Inc. | Aminothiazole modulators of beta-3-adrenoreceptor |
| US8354403B2 (en) | 2009-08-27 | 2013-01-15 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| US8604038B2 (en) | 2009-08-27 | 2013-12-10 | Merck Sharp & Dohme Corp. | Pyrrolidine derived beta 3 adrenergic receptor agonists |
| US20120202819A1 (en) | 2009-10-07 | 2012-08-09 | Merck Sharp & Dohme Corporation | Combination therapy using a beta 3 adrenergic receptor agonists and an antimuscarinic agent |
| CA2796877A1 (en) | 2010-04-30 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel beta 3 adrenergic receptor agonists |
| US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
| WO2016004056A1 (en) | 2014-07-03 | 2016-01-07 | Velicept Therapeutics, Inc. | Pharmaceutical combinations |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| PE20131341A1 (es) * | 2010-08-03 | 2013-12-07 | Altherx Inc | Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva |
| US20120289560A1 (en) | 2011-05-10 | 2012-11-15 | Theravida, Inc. | Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder |
| TW201338772A (zh) | 2012-02-09 | 2013-10-01 | Altherx Inc | 藥學組合物 |
| TW201424772A (zh) | 2012-08-31 | 2014-07-01 | Astellas Pharma Inc | 經口投與用醫藥組成物 |
| US20150306170A1 (en) | 2012-11-21 | 2015-10-29 | Ferring B.V. | Composition for immediate and extended release |
| EP2961730A2 (en) | 2013-02-26 | 2016-01-06 | XenoPort, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| US20160113913A1 (en) * | 2013-04-19 | 2016-04-28 | Takeda Pharmaceutical Company Limited | Controlled-release drug formulation |
| CN105579057A (zh) | 2013-07-23 | 2016-05-11 | 阿勒根公司 | 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物 |
| MX2016010213A (es) | 2014-02-07 | 2017-04-13 | Auspex Pharmaceuticals Inc | Formulaciones farmaceuticas novedosas. |
| JP2017078023A (ja) | 2014-02-28 | 2017-04-27 | アステラス製薬株式会社 | 経口投与用医薬組成物 |
| MX2017007054A (es) | 2014-12-03 | 2018-05-02 | Velicept Therapeutics Inc | Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior. |
| CN108290824B (zh) | 2015-10-23 | 2022-03-11 | B3Ar治疗股份有限公司 | 索拉贝隆两性离子及其应用 |
| EP3448366A1 (en) | 2016-04-25 | 2019-03-06 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
| WO2017210696A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder |
| WO2017210700A1 (en) | 2016-06-03 | 2017-12-07 | Velicept Therapeutics, Inc. | Compositions and methods of using modified release solabegron for lower urinary tract symptoms |
-
2015
- 2015-12-03 MX MX2017007054A patent/MX2017007054A/es unknown
- 2015-12-03 AU AU2015358378A patent/AU2015358378A1/en not_active Abandoned
- 2015-12-03 HK HK18104631.7A patent/HK1245117A1/zh unknown
- 2015-12-03 CA CA2969405A patent/CA2969405A1/en not_active Abandoned
- 2015-12-03 JP JP2017548369A patent/JP2017537165A/ja not_active Ceased
- 2015-12-03 US US14/958,610 patent/US9956194B2/en active Active
- 2015-12-03 EA EA201791225A patent/EA201791225A1/ru unknown
- 2015-12-03 CN CN201580074649.0A patent/CN107205964A/zh active Pending
- 2015-12-03 EP EP15865588.6A patent/EP3226849A4/en not_active Withdrawn
- 2015-12-03 WO PCT/US2015/063795 patent/WO2016090168A1/en not_active Ceased
- 2015-12-03 KR KR1020177018393A patent/KR20170086659A/ko not_active Withdrawn
-
2017
- 2017-06-01 IL IL252628A patent/IL252628A0/en unknown
-
2018
- 2018-04-12 US US15/951,968 patent/US10751311B2/en active Active
- 2018-04-12 US US15/951,953 patent/US20190083433A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhou et al. | Dulaglutide ameliorates STZ induced AD-like impairment of learning and memory ability by modulating hyperphosphorylation of tau and NFs through GSK3β | |
| Anbazhagan et al. | GLP-1 nanomedicine alleviates gut inflammation | |
| Yamawaki et al. | Nrf2 activator for the treatment of kidney diseases | |
| JP2026027257A (ja) | うつ病の治療のためのエスケタミン | |
| JP2024530310A (ja) | Ｔ細胞リンパ腫治療薬の調製におけるｅｚｈ２阻害剤の使用 | |
| EP3038654B1 (en) | New use | |
| Karuppagounder et al. | Naringenin ameliorates daunorubicin induced nephrotoxicity by mitigating AT1R, ERK1/2-NFκB p65 mediated inflammation | |
| US20220000824A1 (en) | Treatment of pulmonary arterial hypertension using therapeutically effective oral doses of 10-nitro-9(e)-octadec-9-enoic acid | |
| JP6957455B2 (ja) | ベータ細胞の複製及び／または生存の亢進 | |
| Khan et al. | Current updates in the medical management of obesity | |
| Abdul-Rahman et al. | The power of three: Retatrutide's role in modern obesity and diabetes therapy | |
| EP3463307A1 (en) | Compositions and methods of using modified release solabegron for lower urinary tract symptoms | |
| EP3518936B1 (en) | Pharmaceutical composition for treatment of non-alcoholic fatty liver disease | |
| MX2012014334A (es) | Tratamiento de diabetes tipo 2. | |
| Yao et al. | Ganoderma lucidum polysaccharide ameliorated diabetes mellitus-induced erectile dysfunction in rats by regulating fibrosis and the NOS/ERK/JNK pathway | |
| Preston et al. | Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study | |
| AU2020201980A1 (en) | Combination of FXR agonists | |
| Tilinca et al. | THE NEWEST THERAPEUTICALLY APPROACH OF" DIABESITY" USING GLP-1 RA MOLECULES: IMPACT OF THE ORAL FORMULATION. | |
| AU2007280636B2 (en) | Delayed-release glucocorticoid treatment of rheumatoid disease | |
| Cha et al. | Repurposing of anti-diabetic agents for the treatment of cognitive impairment and mood disorders | |
| EP4000630B1 (en) | Incretin for elevated intracranial pressure treatment | |
| Igel et al. | Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus | |
| JP2021535106A5 (enExample) | ||
| SK8572003A3 (en) | Histamine receptor antagonists | |
| Greeviroj et al. | Effect of canagliflozin in non-diabetic obese patients with albuminuria: A randomized, double-blind, placebo-controlled trial |